Find → Understand → Decide
Fluorouracil
Discovery priority: LOW · POSSIBLE / INVESTIGATE
Discovery priority ≠ investment recommendation. These are observation labels, not verified canonical products. Buyer qualification: UNKNOWN.
Why investigate?
Why stranded (event context): inadequate public evidence
Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established
Company/trial failed before biology? UNKNOWN
Biology implicated: UNCLEAR · Failure context: UNKNOWN
MODEL INFERENCE · LOW confidence. Explicit asset-linked program event or documented experimental trial arm, stop scope, dated recency and biological cautions; no publication count or buyer-gate input.
Current control: UNKNOWN · Restart: UNKNOWN · Development reuse: UNKNOWN
Next diligence: Confirm present program status and exact product identity, then trace scoped rights/data/CMC and review arm-level human outcomes.
Existing buyer gates
Human Signal: UNKNOWN
Cheap Truth: UNKNOWN
Clean Rights: UNKNOWN
Market Pull: UNKNOWN
No event or publication count supplies missing gate evidence. Existing reviewed opportunities remain in their original records.
Evidence timeline
2026-03-30 · trial:NCT02366819
Registry update date, not proven program-stop date
SOURCE TEXT · Exact source
Pending data analysis
Trial reason is not attributed to every intervention; comparator/combination context needs review.
Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM
Provenance and retrieval scope
{
"hash": "65c7d6f087c172aeda3483c23951e55d7aa45574722be9f7bd2a007401fce769",
"metadata": {
"complete": false,
"content_hash": "38a1f6b0acab83e32f1bc4be6780a423f51adefad10b1134fa1db1296649450e",
"failed": false,
"last_checked": 1790026984.0751398,
"last_success": 1790026984.0751398,
"live_verified": true,
"scope": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
},
"path": "protocolSection.armsInterventionsModule.interventions",
"raw_hash": "38a1f6b0acab83e32f1bc4be6780a423f51adefad10b1134fa1db1296649450e",
"raw_path": "research/obz7_sources/38a1f6b0acab83e32f1bc4be6780a423f51adefad10b1134fa1db1296649450e.json",
"request_params": {
"countTotal": "true",
"format": "json",
"pageSize": 100,
"query.term": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
"sort": "LastUpdatePostDate:desc"
},
"request_url": "https://clinicaltrials.gov/api/v2/studies",
"type": "clinicaltrials",
"url": "https://clinicaltrials.gov/study/NCT02366819"
}2026-07-01 · trial:NCT01871571
Registry update date, not proven program-stop date
SOURCE TEXT · Exact source
Insufficient Accrual
Trial reason is not attributed to every intervention; comparator/combination context needs review.
Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM
Provenance and retrieval scope
{
"hash": "b48bcb7cf02dd10430ccd1eebd10aa315f00ce89f5bc1d9b816cc0a786340605",
"metadata": {
"complete": false,
"content_hash": "0e3eac157b6bfeb4b79d12ac63d9568e02e2be5b2c97d85cda2cc0e3aea17bb7",
"failed": false,
"last_checked": 1790026980.1182604,
"last_success": 1790026980.1182604,
"live_verified": true,
"scope": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
},
"path": "protocolSection.armsInterventionsModule.interventions",
"raw_hash": "0e3eac157b6bfeb4b79d12ac63d9568e02e2be5b2c97d85cda2cc0e3aea17bb7",
"raw_path": "research/obz7_sources/0e3eac157b6bfeb4b79d12ac63d9568e02e2be5b2c97d85cda2cc0e3aea17bb7.json",
"request_params": {
"countTotal": "true",
"format": "json",
"pageSize": 100,
"query.term": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
"sort": "LastUpdatePostDate:desc"
},
"request_url": "https://clinicaltrials.gov/api/v2/studies",
"type": "clinicaltrials",
"url": "https://clinicaltrials.gov/study/NCT01871571"
}2026-07-17 · trial:NCT00707473
Registry update date, not proven program-stop date
SOURCE TEXT · Exact source
\<75% participation
Trial reason is not attributed to every intervention; comparator/combination context needs review.
Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM
Provenance and retrieval scope
{
"hash": "ae92e73735ca07ecbe405086dedf33e2971d3635b466ff22e9ab880db34f3756",
"metadata": {
"complete": false,
"content_hash": "0e3eac157b6bfeb4b79d12ac63d9568e02e2be5b2c97d85cda2cc0e3aea17bb7",
"failed": false,
"last_checked": 1790026980.1182604,
"last_success": 1790026980.1182604,
"live_verified": true,
"scope": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
},
"path": "protocolSection.armsInterventionsModule.interventions",
"raw_hash": "0e3eac157b6bfeb4b79d12ac63d9568e02e2be5b2c97d85cda2cc0e3aea17bb7",
"raw_path": "research/obz7_sources/0e3eac157b6bfeb4b79d12ac63d9568e02e2be5b2c97d85cda2cc0e3aea17bb7.json",
"request_params": {
"countTotal": "true",
"format": "json",
"pageSize": 100,
"query.term": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
"sort": "LastUpdatePostDate:desc"
},
"request_url": "https://clinicaltrials.gov/api/v2/studies",
"type": "clinicaltrials",
"url": "https://clinicaltrials.gov/study/NCT00707473"
}Freshness is claim-specific
Fetching an old filing today does not establish current ownership or program status.
pipeline · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
sec · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
rights · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
contact · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
patent_assignment · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
clinicaltrials · STALE · AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:00.118260+00:00
clinicaltrials · STALE · AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:00.118260+00:00
clinicaltrials · STALE · AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:04.075140+00:00
Registry observations (3)
NCT00707473 · TERMINATED · PHASE2 · Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma; Sinonasal Undifferentiated Carcinoma; Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8; Stage III Nasal Cavity and Paranasal Sinus Cancer AJCC v8; Stage IVA Nasal Cavity and Paranasal Sinus Cancer AJCC v8; Stage IVB Nasal Cavity and Paranasal Sinus Cancer AJCC v8 · Trial sponsor M.D. Anderson Cancer Center
Reported aliases: 5-Fluoro-2,4(1H, 3H)-pyrimidinedione; 5-Fluorouracil; 5-Fluracil; 5-FU; AccuSite; Carac; Fluoro Uracil; Fluouracil; Flurablastin; Fluracedyl; Fluracil; Fluril; Fluroblastin; Ribofluor; Ro 2-9757; Ro-2-9757. Identity, treatment role and exposure require review.
NCT01871571 · TERMINATED · PHASE2 · Mucinous Adenocarcinoma of the Rectum; Signet Ring Adenocarcinoma of the Rectum; Stage IIA Rectal Cancer; Stage IIB Rectal Cancer; Stage IIC Rectal Cancer; Stage IIIA Rectal Cancer; Stage IIIB Rectal Cancer; Stage IIIC Rectal Cancer · Trial sponsor University of Southern California
Reported aliases: 5-fluorouracil; 5-Fluracil; 5-FU. Identity, treatment role and exposure require review.
NCT02366819 · SUSPENDED · PHASE4 · Esophageal Adenocarcinoma; Gastric Adenocarcinoma; Stage IIB Gastric Cancer; Stage IIIA Esophageal Adenocarcinoma; Stage IIIA Gastric Cancer; Stage IIIB Esophageal Adenocarcinoma; Stage IIIB Gastric Cancer; Stage IIIC Esophageal Adenocarcinoma; Stage IIIC Gastric Cancer · Trial sponsor University of Chicago
Reported aliases: None. Identity, treatment role and exposure require review.